Northwest Biotherapeutics Inc
Northwest Biotherapeutics Inc. is a U.S.-based biotechnology company focused on dendritic cell-based cancer immunotherapies. Its core programs center on DCVax-L for solid tumors such as glioblastoma and DCVax-Direct, alongside related manufacturing, process development, and clinical trial activities in the U.S. and Europe.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueAutologous dendritic cell therapy designed for surgically resectable solid tumors, including glioblastoma.
Intratumoral dendritic cell therapy program intended for tumors that can be injected directly.
Clinical trial planning, regulatory preparation, and investigator/site coordination for oncology programs.
Cell therapy manufacturing, quality control, and facility build-out supporting product supply.
Expanded access treatment programs for patients seeking DCVax therapies outside trials.
Customers
The company’s direct customers are not traditional commercial buyers; its programs are aimed at hospitals, clinicians, and clinical investigators that administer or study its therapies. Patients with difficult-to-treat solid tumors are the end beneficiaries, while expanded-access and compassionate-use arrangements create additional clinical channels. In practice, demand is driven by oncology centers, trial sites, and physicians seeking novel cell-based treatment options where standard therapies are limited.
Hospitals and research centers that enroll patients, administer protocols, and generate clinical data for DCVax programs.
Oncology specialists who evaluate, refer, and treat patients within study or expanded-access settings.
Patients with glioblastoma and other solid tumors who receive therapy through trials or compassionate use.
Academic and institutional partners that support manufacturing, trial design, and translational work.
Strategy
The company is focused on advancing DCVax programs through clinical development, manufacturing readiness, and regulatory preparation. A major priority is building the operational infrastructure needed for cell therapy production and trial execution, while also pursuing expanded-access pathways that can generate real-world treatment experience. It is also broadening its technology base through in-licensed assets and related dendritic cell approaches that may complement the core platform.
Clinical validation is essential for any future commercialization and partner interest.
Cell therapies depend on reliable GMP manufacturing, equipment, and trained staff.
Compassionate-use programs can support patient access and generate practical treatment data.
In-licensed and complementary dendritic cell technologies may extend the pipeline beyond one asset.
Geography
The company is headquartered in the United States but conducts meaningful development activity in the U.K. and other European locations through subsidiaries and clinical operations. Its Sawston, U.K. facility is central to manufacturing and process development, while U.S. activities include manufacturing planning, clinical development, and expanded-access exploration. The company also references subsidiaries in the U.K., the Netherlands, and Germany, reflecting a cross-border operating footprint for a cell therapy business.
Risks
The company faces the typical risks of a pre-commercial biotechnology developer: clinical failure, regulatory delays, manufacturing setbacks, and dependence on external financing. Its cross-border operations also create execution and foreign-exchange exposure, while cell therapy development adds complexity around GMP supply, site readiness, and product consistency. Litigation, patent protection, and the ability to maintain access to capital are additional company-specific risks that can materially affect progress.
The company has not established recurring operating revenue and relies on external capital.
Exposure: Corporate funding and operations
The company depends on successful trial design, enrollment, and outcomes for DCVax programs.
Exposure: DCVax-L and DCVax-Direct
Cell therapies require extensive regulatory review and may face delays or requests for more data.
Exposure: UK MAA and future trial submissions
Cell therapy production depends on specialized equipment, facilities, and qualified personnel.
Exposure: Sawston and U.S. GMP sites
A meaningful portion of activity is tied to the U.K. and other non-U.S. operations.
Exposure: GBP/USD translation and transaction effects
Ongoing legal proceedings can create cash costs, uncertainty, and management distraction.
Exposure: Market maker litigation
Accounting
Judgemental itemsClinical trial, manufacturing, and regulatory costs are expensed as incurred and drive reported losses.
Impact: Period-to-period volatility in operating results
Clinical sites, consultants, and legal services require estimates before invoices are finalized.
Impact: Potential true-up adjustments in later periods
Fair-value changes on derivatives can materially affect non-operating results.
Impact: Earnings volatility unrelated to core operations
Equity awards are a meaningful non-cash expense for a development-stage company.
Impact: Affects operating expense and dilution analysis
U.K. operations and GBP exposure can create gains or losses versus the U.S. dollar.
Impact: Non-operating volatility in reported results
Similar listed companies
Publicly listed companies with a comparable business focus.
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Nuvation Bio Inc.
NUVB · Pharmaceutical Preparations
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Nuvectis Pharma, Inc.
NVCT · Pharmaceutical Preparations
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
Last updated: 29/04/2026